Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2023-03-15 Earnings Release
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Kuros Biosciences reports results for the full year 2022
Earnings Release Classification · 95% confidence The document is titled "Kuros Biosciences reports results for the full year 2022" and contains detailed financial highlights, operational highlights, outlook, and a full table of key financial figures comparing 2022 results to 2021. This structure is characteristic of an Earnings Release (ER) or a comprehensive Interim/Annual Report. Since it covers the 'full year 2022' and provides extensive financial detail (including a full income statement structure in the table), it strongly suggests a comprehensive annual filing. However, the document is released on March 15, 2023, and explicitly mentions the 'annual report 2022 is available on our corporate website' with a link, and it also announces a future call to discuss the results. This pattern—releasing key results and financial summaries while directing users to the full Annual Report (10-K equivalent) elsewhere—is typical of an Earnings Release (ER). Given the comprehensive nature of the financial data presented here, it leans towards being the primary release of the annual results, which aligns best with the Earnings Release (ER) definition, rather than just a short announcement (RPA). It is not the 10-K itself, but the press release announcing the results that would typically precede or accompany the 10-K filing. FY 2022
2023-03-15 English
Kuros Biosciences reports results for the full year 2022
Earnings Release Classification · 100% confidence The document is titled 'Kuros Biosciences reports results for the full year 2022' and contains detailed financial highlights, operational highlights, and a full table of key financial figures comparing 2022 results to 2021. This structure is characteristic of a comprehensive annual financial disclosure. Although it is presented as an 'Ad hoc announcement pursuant to Art. 53 LR' (a regulatory requirement for material information), the content itself is the substance of the full-year financial results, which aligns most closely with the Annual Report (10-K) definition, or potentially an Interim/Quarterly Report (IR) if it were for a shorter period. Since it explicitly covers 'full year 2022' results and includes detailed financial statements/tables, it functions as the primary annual financial disclosure. However, the document explicitly states: 'The annual report 2022 is available on our corporate website under the following link:'. This suggests the current document is the *release* or *summary* of the annual results, rather than the full 10-K filing itself. Given the detailed financial data provided (revenue, costs, net loss, balance sheet items), it is more substantial than a simple Earnings Release (ER). It is a comprehensive summary of annual results, often released before or instead of the formal 10-K filing in non-US jurisdictions, but it is not a Report Publication Announcement (RPA) because it contains the core data, not just a link. Since it covers the full year and provides detailed financial performance metrics, it is best classified as an Annual Report (10-K) proxy or the primary annual disclosure, even if the formal 10-K document is linked separately. If a specific 'Annual Report' code existed for non-US filings, it would be used, but among the choices, 10-K is the closest analogue for a full-year financial disclosure. FY 2022
2023-03-15 English
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
Legal Proceedings Report Classification · 99% confidence The document is a press release dated February 21, 2023, from Kuros Biosciences AG announcing the 'Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft' in peer-reviewed journals. It details scientific findings and quotes the CEO. This is not a formal regulatory filing like a 10-K, 10-Q (IR), or a specific financial report (ER, AR). It is an announcement about scientific/research progress, which often falls under general investor relations or regulatory news. Since it is a general news announcement about scientific data publication and does not fit the specific categories like ER, AR, or IP, the most appropriate general category is Regulatory Filings (RNS) as a catch-all for corporate news releases that aren't explicitly defined elsewhere, or potentially Investor Presentation (IP) if the content were structured as a presentation, but here it reads like a news update about published research. Given the context of a company issuing news about published data, RNS (Regulatory Filings/General Announcement) is the best fit among the provided options, as it is a general corporate communication.
2023-02-21 English
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
Regulatory Filings Classification · 99% confidence The document is a press release from Kuros Biosciences AG announcing the publication of scientific data regarding their MagnetOs bone graft in peer-reviewed journals. It details scientific findings, quotes the CEO, and provides contact information. This type of announcement, which disseminates new scientific or operational information outside of mandatory financial reporting cycles (like 10-K or ER), fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous corporate announcement, or potentially as an Investor Presentation (IP) if it were a slide deck, but since it's a news release about published research, RNS is the most appropriate general regulatory/news category when a more specific scientific disclosure category is absent. It is not a formal financial report (10-K, IR, ER, MRQ), nor is it a management change (MANG) or a dividend notice (DIV). Given the context of a news release announcing scientific validation, RNS serves as the best fit among the provided options for a general corporate disclosure.
2023-02-21 English
Kuros Biosciences Announces Changes to Executive Management Team
Board/Management Information Classification · 100% confidence The document is an 'Ad hoc announcement' dated February 16, 2023, explicitly stating it is released pursuant to the SIX listing rules. The core content announces a change in senior personnel: the appointment of a new Chief Financial Officer (CFO) ad interim and the departure of the previous CFO. This directly matches the definition for 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-02-16 English
Kuros Biosciences Announces Changes to Executive Management Team
Board/Management Information Classification · 100% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and explicitly states 'Kuros Biosciences Announces Changes to Executive Management Team'. The content details the appointment of a new Chief Financial Officer (CFO) ad interim, Daniel Geiger, succeeding Michael Grau. This directly corresponds to the definition of Board/Management Information, which covers announcements of changes in senior management.
2023-02-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.